David M. Knott’s Cymabay Therapeutics CBAY Stock Holding History

David M. Knott’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-80,889	Closed	-$413K	–	123
2019 Q3	$413K	Buy	80,889 +59,889	+285%	+$363K	0.17%	63
2019 Q2	$150K	Buy	+21,000	New	+$238K	0.06%	81
2018 Q4	–	Sell	-63,000	Closed	-$698K	–	108
2018 Q3	$698K	Buy	63,000 +43,000	+215%	+$534K	0.23%	51
2018 Q2	$268K	Buy	+20,000	New	+$250K	0.1%	80

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

David M. Knott's CBAY Position: Q4 2019 in Review

David M. Knott sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 80,889 shares — an estimated $413K sold.

David M. Knott first reported a position in CBAY in Q2 2018 and held it in 4 quarters. The position peaked at $698K in Q3 2018. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

David M. Knott reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
David M. Knott sold 80,889 Cymabay Therapeutics shares in Q4 2019, an estimated $413K.
David M. Knott first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 4 quarters.
David M. Knott's Cymabay Therapeutics position peaked at $698K in Q3 2018.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on David M. Knott's 13F filing for Q4 2019, filed 14 Feb 2020.